Latest From Biotech Now

It’s been just over 15 years since James Thomson first isolated embryonic stem cells in his lab at the University of Wisconsin-Madison. In that time, some remarkable advances have been made. Namely, I’m talking about the ability to transform adult human cells into extremely useful pluripotent stem cells. A new treatment using pluripotent cells could potentially repair and regenerate damaged heart tissue. In a 2013 study published in The Lancet, Dr. Eduardo Marban, director of Read More >

Day two of the 16th Annual BIO CEO & Investor Conference​ kicked off with a Fireside Chat featuring one of the longest tenured pharma CEOs, David E.I. Pyott, Chairman of the Board & Chief Executive Officer, Allergan. The Chat, moderated by Seamus Fernandez, Managing Director, Major and Specialty Pharmaceuticals, Leerink Partners LLC, explored the multi-specialty healthcare model that Allegran has found success in which few realize is not just ophthalmology. Allergan has also found success in neurosciences, medical dermatology, dermal fillers and urologics. Read More >

One of the most important keys to successful relationships – be it in life or rare disease drug development – is open, honest and frequent communication, according to a panel of rare disease experts speaking at the Therapeutic Workshop: “Balancing the Rick-Reward in Rare Disease Drug Development” at the BIO CEO & Investor Conference in New York on Monday. Without engaging the key groups at the right time and the right manner, companies entering this Read More >

Biology Fortified (BFI) is launching a Kickstarter fundraising campaign to fund the creation of 500 copies of their blog mascot, Frank N. Foode™. Frank N. Foode™, an adorable plush GM corn, was first handcrafted in 2009 by Karl Haro von Mogel to remind us of the important role that agriculture plays in our everyday lives. This iconic symbol has gotten his photo taken with people, plants, and in exotic places, all to help make the Read More >

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >